Physician profile
Donna Lynn Stephens
NPI 1376529503
$8,362.79
in general payments reported to CMS, 2019-2025
38 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $1,048 · 2021: $1,121 · 2022: $778 · 2023: $1,322 · 2024: $1,668 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,229.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,728.58 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $1,032.76 | 2020-2025 | Jardiance, Mounjaro, Trulicity |
| Novo Nordisk INC | $830.75 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $759.08 | 2019-2025 | Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $664.91 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.37 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $432.13 | 2022-2025 | |
| Amgen INC. | $427.56 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $303.37 | 2019-2025 | |
| Abbott Laboratories | $215.27 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $148.47 | 2019-2021 | |
| Astellas Pharma US INC | $110.13 | 2023-2024 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $108.46 | 2020-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $105.03 | 2021 | |
| Exact Sciences Corporation | $102.42 | 2023-2025 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.